XOMA Royalty Corp XOMA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $27.27
- Day Range
- $25.97–26.91
- 52-Week Range
- $13.45–30.34
- Bid/Ask
- $0.00 / $0.00
- Market Cap
- $308.18 Mil
- Volume/Avg
- 8,547 / 23,683
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 40.12
- Dividend Yield (Trailing)
- 1.97%
- Dividend Yield (Forward)
- 7.88%
- Total Yield
- 1.97%
Company Profile
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 13
- Website
- https://www.xoma.com
Comparables
Valuation
|
Metric
|
XOMA
|
PTGX
|
NYKD
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 16.79 | — |
Price/Book Value | 3.19 | 4.88 | 0.87 |
Price/Sales | 40.12 | 8.72 | 22.04 |
Price/Cash Flow | — | 13.96 | — |
Price/Earnings
XOMA
PTGX
NYKD
Financial Strength
|
Metric
|
XOMA
|
PTGX
|
NYKD
|
|---|---|---|---|
Quick Ratio | 8.56 | 13.60 | 9.28 |
Current Ratio | 8.71 | 13.73 | 9.28 |
Interest Coverage | — | — | — |
Quick Ratio
XOMA
PTGX
NYKD
Profitability
|
Metric
|
XOMA
|
PTGX
|
NYKD
|
|---|---|---|---|
Return on Assets (Normalized) | −1.98% | 44.65% | −17.82% |
Return on Equity (Normalized) | −3.86% | 49.43% | −22.35% |
Return on Invested Capital (Normalized) | −2.20% | 44.16% | −25.52% |
Return on Assets
XOMA
PTGX
NYKD
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Pszcpvgpz | Ssy | $518.0 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Nmfydtxx | Wccphqv | $119.3 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Qqhlgnj | Klvrvp | $114.7 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Ygnwhysx | Gpmvyjr | $34.9 Bil | |||
| argenx SE ADR
ARGX
| Ddzjlpym | Tnks | $32.9 Bil | |||
| BioNTech SE ADR
BNTX
| Spwsqgrp | Cnqmr | $28.3 Bil | |||
| Moderna Inc
MRNA
| Ndthpbnj | Wvhlc | $24.3 Bil | |||
| United Therapeutics Corp
UTHR
| Bxkxftjl | Wmtz | $15.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Hdwmxjq | Gvzjmv | $13.3 Bil | |||
| Incyte Corp
INCY
| Cmhlhmk | Kpfgx | $13.0 Bil |
United States